artificial aortocaval fistula (for 105 days)

 sham surgical control condition (for 2 days) then Aprotinin (12000 kIU) (for 2 days)

 artificial aortocaval fistula (for 2 days) then Aprotinin (12000 kIU) (for 2 days)

 left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days)

 left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days)

 artificial aortocaval fistula (for 2 days)

 control condition (for 28 days)

 artificial aortocaval fistula (for 28 days)

 vehicle control condition

 artificial aortocaval fistula (for 28 days) then Aprotinin (12000 kIU) (for 28 days)

 sham surgical control condition (for 196 days)

 controlled sodium content diet (for 21 days)

 sham surgical control condition (for 28 days)

 control condition (for 84 days)

 control condition (for 56 days)

 control condition (for 168 days)

 left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days)

 sham surgical control condition (for 224 days)

 left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days)

 sham surgical control condition (for 2 days)

 sham surgical control condition (for 105 days)

 sham surgical control condition (for 28 days) then Aprotinin (12000 kIU) (for 28 days)

 control condition (for 252 days)

 gene transfer of the rat natriuretic peptide B gene using an adenovirus vector (100000000000 PFU)